Skip to main content

Health & Medicine

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Source: MarketScreener
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Alnylam Pharmaceuticals and Inceptive have announced a strategic partnership valued at up to $2 billion focused on AI-driven drug discovery. The deal combines Alnylam's expertise in RNA interference therapeutics with Inceptive's artificial intelligence capabilities to accelerate the development of new medicines. This collaboration represents a significant investment in leveraging AI technology to streamline the drug discovery process.

Read Full Article at MarketScreener

Related Articles